The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Simple Summary Response to TACE is a surrogate marker of tumor aggressive biology, with
manifold practical implications. In turn, inflammation-based scores are biomarkers of the …

Purpose To evaluate the efficacy and safety of lenvatinib combined with programmed death
receptor-1 signaling inhibitors plus transarterial chemoembolization (LePD1-TACE) for …

Background Since atezolizumab plus bevacizumab (ATE+ BEV) regimen for patients with
unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data …

Aim We investigated pretreatment neutrophil‐to‐lymphocyte ratio (NLR) for predicting
survival outcomes of atezolizumab plus bevacizumab therapy for hepatocellular carcinoma …

Background Monocyte to lymphocyte ratio (MLR) represents a pro-inflammatory immune
microenvironment. The aim of this study was to elucidate the effect of MLR and subsequent …

Simple Summary Percutaneous interventional radiological techniques offer many
alternatives for treatment of Hepatocellular Carcinoma (HCC) using local anesthesia and …

Simple Summary Patients with locally advanced rectal cancer who achieve a pathological
complete response to neoadjuvant chemoradiotherapy have been associated with excellent …

Objectives To evaluate the safety and efficacy of chemoembolization in patients with
intermediate-stage infiltrative Hepatocellular carcinoma (HCC). Materials and methods This …

Hepatocellular carcinoma (HCC) is associated with high mortality, especially in Asian
populations where chronic HBV infection is a major cause. Accurate prediction of mortality …